FDA Will Require Class-Wide REMS For Opioids; “Massive” Program Compared To Past Efforts
This article was originally published in The Pink Sheet Daily
Executive Summary
Class-wide REMS will encompass 24 marketed products from 16 different manufacturers; focus on extended-release products.
You may also be interested in...
Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs, FDA Says
Office of New Drugs Director John Jenkins explains the agency’s options in approving pending potent opioids in lieu of a class-wide REMS.
Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs, FDA Says
Office of New Drugs Director John Jenkins explains the agency’s options in approving pending potent opioids in lieu of a class-wide REMS.
Class-Wide REMS For Opioids: A Look At The Products Affected
Class-Wide REMS For Opioids